SET and urinary bladder cancer: Notably, C18-ceramide was higher in chemoresistant bladder cancer (Additional file 2: Fig. S3G), and it has been reported to bind to inhibitor 2 of PP2A (I2PP2A), inhibiting its activity and thereby activating PP2A [52, 53].